Cipla share price added 4 percent in the early trade on September 25 after the company received USFDA approval for a multiple sclerosis drug.
The company has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pak from the United States Food and Drug Administration (US FDA), the pharma major said in a release.
Dimethyl Fumarate DR Caps Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc’s Tecfidera.
It is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
The product is available for shipping immediately and the company will provide Co-Pay Assistance.
According to IQVIA (IMS Health), Tecfidera had US sales of approximately $3.8 billion for the 12-month period ending July 2020.
At 0923 hours, Cipla was quoting at Rs 753.35, up Rs 20.55, or 2.80 percent on the BSE.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
